I operate at the intersection of AI, human genetics, and commercial strategy. At Genomics, I help pharmaceutical and biotech organizations bring large-scale human genetics into earlier, more confident R&D decision-making—through a combination of advanced analytics, AI-enabled tooling, and strategic consulting support.

My work centers on partnering with senior R&D, statistical genetics, and strategy leaders to operationalize genetics across the pipeline: accelerating target discovery, strengthening validation, improving translational confidence, and identifying patient populations more likely to respond to therapy.

Over the past 20 years, I’ve:

•	Built, led, and mentored high-performing sales teams in AI and SaaS.
•	Managed global accounts and developed go-to-market strategies that drive adoption.
•	Closed multi-million-dollar enterprise engagements and partnerships across R&D industries 
•	Negotiated strategic agreements that expand revenue and accelerate growth.

I’m also the author of Mastering AI Sales: Essential Knowledge for B2B Professionals, a practical playbook that equips founders, consultants, and sales leaders with frameworks to win complex AI sales.
👆 Now available – click the link in my profile header to get your copy.

Specialties

•	AI-Enabled Human Genetics / Genomics Commercial Strategy
•	Building & Scaling Sales Teams
•	Enterprise AI Sales & Stakeholder Management
•	Go-to-Market Strategy (Consulting + Product Hybrid Models)
•	Strategic Partnerships & Revenue Expansion
•	Cross-Functional Leadership & Commercial Alignment

Let’s connect if you’re scaling AI solutions, leading enterprise transformations, or looking to accelerate sales impact in complex markets.

David Walker

Early JPM takeaways…

• Causal genetics is firmly front and center, increasingly used to de-risk target identification and validate programs earlier in development.
• Patient stratification is no longer optional. Leaders are entering the clinic with greater emphasis on clear responder hypotheses and stronger supporting evidence.
• AI is maturing quickly. Fewer proof-of-concept discussions, more concrete examples of measurable impact across R&D.
• Funding sentiment appears cautiously improved, particularly for companies with differentiated science and disciplined, evidence-led strategies.

The Genomics leadership team is here all week and we’d be happy to connect and compare notes.

#jpm2026 #Genomics

VP of Client Service | Leading Enterprise AI Partnerships | Team Builder | Author of Mastering AI Sales | MBA, MSc.

JPM was an outstanding experience. The energy, quality of conversations, and level of innovation throughout the week were exceptional.

We were delighted to host a Genomics reception, where we shared how Mystra, our AI enabled platform, enables teams to apply human genetics more effectively to R&D decision-making. The depth of engagement reinforced just how central genetics has become to smarter target selection and clinical decisions.

A few key takeaways stood out for me…

1. Platforms must change decisions
AI creates value only when it changes decisions e.g. which targets advance, which programs stop earlier, and which patients enter trials. The strongest platforms enable fewer, higher-confidence bets.

2. Data advantage ≠ more data
The ultimate advantage is signal, not scale. Rare disease cohorts, longitudinal datasets, and multi-omics data with clinical context enable better questions to be asked and reduce false confidence.

3. Causal genetics is becoming foundational
Human genetics is increasingly being used to improve probability of success, de-risk programs earlier, enable patient stratification, and support smarter trial design.

The next phase of R&D won’t be defined by who moves fastest, but by who makes the best decisions earliest, using well-curated data, causal evidence, and AI together.

#JPM26 #Genetics #TargetValidation #PatientStratification #DrugDevelopment

Great to see the Genomics team out in force at #FOG2026 
If you’re at FOG, make sure you stop by by Booth #77 to say hello and check out the Mystra D&D Quest, a fun, hands-on way to experience how we support drug target discovery and development through human genetics and multi-omics.   Plus Dirk Paul, Head of Development, talking about: “The Genome and Beyond: Advancing Drug Discovery and Development” Today 12:00–12:30 | Multi-Omics Stage
Have a great show, team 👋
#DrugDiscovery #MultiOmics #Genomics #DrugDevelopment #FOG2026 #FrontLineGenomics

Day 1 at #FOG2026 is here 🚀 

You can find us at Booth #77 - come say hello to the team and try our iconic Mystra D&D Quest 🧙 - an interactive challenge that gives you a hands-on experience with our drug target discovery and development platform! 

🎤 Today | 12:00 - 12:30 | Multi-Omics stage
Join Dirk Paul, Head of Development, for "The Genome and Beyond: Advancing Drug Discovery and Development"
What to expect:
💡 Insights into Genomics' genotype-phenotype platform & analytical pipelines
🧬  A deep dive into how multi-omics integration drives target identification & data-driven patient stratification
🌍  Real-world case case studies showcasing risk prediction and pharmacomimetic approaches in action

See you on the floor 👋 

#drugdiscovery #MultiOmics #Genomics #DrugDevelopment Front Line Genomics

I'll be heading to JPM next week. If you’ll be there too, drop me a message, it’d be great to connect in person.

🎉 We're starting the year in San Francisco! Our team will be arriving later this week for the J.P. Morgan Healthcare Conference.

We are looking forward to a busy few days connecting with colleagues from the Department for Business and Trade, and senior leaders across pharma and biotech.

From Saturday, January 10th, our CEO and Co-Founder, Professor Sir Peter Donnelly, President David Thornton, VP of Client Service David Walker, and Director of Communications Zuzanna Grzeskiewicz will be on the ground in San Francisco, ready to connect.

If you're going to be in San Francisco next week and would like to meet with our team, click here: https://lnkd.in/eT9qFMyy

See you soon! 🚀 

#JPM2026 #JPMWeek #techbio #genomics #JPM #pharma #biotech #healthcare #SanFran

Quantori

Quantori is at the forefront of transforming drug discovery with a unique value proposition that combines deep scientific domain knowledge with data science and advanced analytics expertise, and software engineering excellence. Our mission is to help biopharma companies speed up discovery of viable drug candidates to deliver new therapies to patients worldwide and optimize treatments for precision healthcare.

Principal and Chief Scientific Officer

Felicitex Therapeutics Inc.

Founder & board member of therapeutics company that develops novel treatments for dormant cancers - targeting resistance, metastasis, and relapse. Felicitex therapies specifically target and kill cancer cells that use the dormancy state for their survival niche.

Cofounder, Scientific Advisory and Board of Directors

EPAM Systems

Joined EPAM as a result of the acquisition of GGA Software Services. Led business development, account and delivery management, and provision of consulting services to clients of EPAM's Life Sciences business unit.

Chief Life Sciences Officer and Vice President

GGA Software Services

Founded leading provider of scientific software engineering, algorithm development, and knowledge management solutions for the life sciences industry.  Led financial planning, business development, client and delivery management. Managed cross-border team of 300 scientists, software engineers and algorithm developers.

Founder and Chief Scientific Officer

Elsevier

Joined Executive Team after Elsevier acquired ITC. Directed scientific content curation and analysis programs.

Director - Content Database Development

Institute of Theoretical Chemistry (ITC)

Founded research firm that developed bespoke client solutions based on theoretical chemistry. Led research, product, and business development and supervised 100-person team of scientific research and development professionals.

Founder, Co-Owner

Houghton Mifflin Harcourt

Joined Harcourt Management Team as a result of the acquisition of SciVision. Managed 150-person team developing scientific information systems.

Director - Information Systems

SciVision, Inc.

Founded company focused on developing software solutions for modeling of physicochemical properties of proteins and small molecules.

Founder, Director

Institute of Silicate Chemistry of RAS

Conducted experimental research and developed mathematical models for optimizing the properties of glass.

Scientist

Yuriy Gankin, Ph.D., is a life science researcher, serial entrepreneur, and inventor who has over two decades of expertise in helping life sciences, biotech and pharma companies develop IT solutions for accelerating the discovery and development of novel therapies which treat disease and improve the quality of patient lives.

He currently serves as Principal and Chief Scientific and Strategy Officer at Quantori, a developer of intelligent IT and data science solutions for life sciences, pharma, and healthcare organizations. Quantori is at the forefront of transforming drug discovery and healthcare with a unique value proposition that combines advanced analytics, scientific knowledge management, and software engineering excellence.

Previously, Dr. Gankin was Chief Life Sciences Officer and Vice President of the Life Sciences Business Unit at EPAM, following the acquisition of GGA Software Services by EPAM.  As the cofounder of GGA, he helped build the company into a leading provider of scientific software engineering, algorithm development, and data curation services.

Dr. Gankin's research has been published in multiple scientific journals and he holds several patents for targeted cancer therapy. His expertise spans research, database development, and modeling in chemistry and biology. Dr. Gankin holds a Ph.D. in Analytical Chemistry from Tufts University where he is a Visiting Scientist, in addition to an MBA from MIT Sloan.

taplio

The Battle

David Walker

Yuriy Gankin, PhD

Followers

Posts

Engagements

Likes

Performance ScoreDavid Walker's LinkedIn Performance

Ready to grow your LinkedIn presence?

taplio

The Battle

David Walker

Yuriy Gankin, PhD

Followers

Posts

Engagements

Likes

Performance Score.css-goub6s{font-size:var(--chakra-fontSizes-md);font-weight:500;color:var(--chakra-colors-gray-600);display:block;margin-top:var(--chakra-space-1);}David Walker's LinkedIn Performance

Ready to grow your LinkedIn presence?

Performance ScoreDavid Walker's LinkedIn Performance